vitalwiki

Desonide

RxNorm 197572· DESONIDE· TOPICAL

Corticosteroid [EPC] · Alembic Pharmaceuticals Inc.

Indications and usage

INDICATIONS AND USAGE Desonide lotion is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Dosage and administration

DOSAGE AND ADMINISTRATION Desonide lotion should be applied to the affected areas as a thin film two or three times daily depending on the severity of the condition. SHAKE LOTION WELL BEFORE USING. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Desonide lotion should not be used with occlusive dressings.

Contraindications

CONTRAINDICATIONS Desonide lotion is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Adverse events

Most frequently reported events (FDA FAERS). Report frequency does not imply causation.

  • drug ineffective1,161
  • macular degeneration780
  • off label use409
  • pain384
  • nausea371
  • headache320
  • rash313
  • pruritus310
  • erythema308
  • pyrexia301
  • psoriasis280
  • malaise279
  • weight decreased277
  • therapeutic product effect incomplete263
  • abdominal pain223
  • dermatitis atopic221

Adverse reactions (label)

ADVERSE REACTIONS In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide was approximately 8%. These were: stinging and burning approximately 3%, irritation, contact dermatitis, condition worsened, peeling of skin, itching, intense transient erythema, and dryness/scaliness, each less than 2%. The following additional local adverse reactions have been reported infrequently with other topical corticosteroids, and they may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, secondary infection, skin atrophy, striae, and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals, Inc. at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.